Psilocybin-assisted therapy companies make headlines this week

Psyched is back to wrap up the exciting movement of this rapidly evolving sector as a wave of news about psychedelics research and successful applications sweeps across the country and abroad.

Psyence Group Inc. PSYGF received approval from the UK's Medicines and Healthcare Products Regulatory Agency MHRA to evaluate the efficacy and safety of psilocybin-assisted psychotherapy for treating adjustment disorder following an incurable cancer diagnosis in Phase 2 clinical trial.

The adjustment disorder is present in 40% of patients with a terminal diagnosis, affecting the well-being of the patients and their families and potentially leading to overutilization of healthcare resources and medications as coping mechanisms.

Psilocybin can reduce stress and anxiety in patients and provide a better quality of life compared to the low success rate of currently available treatments.

Researchers hope to create a paradigm shift in the treatment of patients with an incurable illness and improve quality of end-of-life and standard care by beginning in the last quarter of 2022 and running for the next 18 months.

Alberta-based ATMA Journey Centers Inc. received Health Canada approval to test its proprietary psilocybin, N 500, in a Phase 2 study looking at the potential relief of COVID 19-associated mental health challenges in frontline healthcare professionals.

The trial could inform the psychedelics-aided therapy world with valuable information regarding the professionals firsthand evaluation of the substance's effects and how it might be applied to patients once legally available, because it will inform on real-world data as to how psychedelic medicine works and how it can be applied to patients once legally available.

ATMA aims to build a therapist-centered business model and be a source for mental healthcare professionals who want to adopt psychedelic-assisted therapy as part of their services.

Leaders of the Native American Church of North America NACNA met with Congressional officials to discuss the possibility of federal funding for the preservation of peyote s endangered natural habitats for future generations.

This Schedule I psychedelic has historical use in religious contexts and NACNA holds federal permission to grow and use it. In 2022, the supply of peyote is limited, so NACNA leaders and the National Congress of American Indians NCAI are asking for $5 million from the Department of Agriculture USDA or the Interior Department to reimburse landowners who make their property a protected habitat for the cacti.

A Swiss clinical trial that tested a combination of MDMA and natural psilocybin and research development for the treatment of obesity and other metabolic syndromes with a combination of a non-hallucinogenic psychedelic compound and cannabinoids and n-acylethanolamines is one of the recent news that psilocybin learns more about its current legal position, scientific stage and experts opinion on microdosing.

Psilocybin products and services continue to thrive. This German company, for instance, is now delivering magic truffles to at-home microdosing therapy in the US, while psychedelics companies organize wellness retreats.

Other substances that are not strictly considered to be part of the psychedelics list have also made headlines this week. Companies that offer legal ketamine-assisted therapy continue to expand their services to reach out to the population in need.